NSTM (NovelStem International) Current Accrued Expense: $0.04 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is NovelStem International Current Accrued Expense?

NovelStem International NSTM Current Accrued Expense is $0.04 Mil as of Jun. 2026. The stock has 3 warning signs investors should review.

NovelStem International's Current Accrued Expense for the quarter that ended in Jun. 2026 was $0.04 Mil.

NovelStem International's quarterly Current Accrued Expense stayed the same from Dec. 2025 ($0.04 Mil) to Mar. 2026 ($0.04 Mil) and stayed the same from Mar. 2026 ($0.04 Mil) to Jun. 2026 ($0.04 Mil).

NovelStem International's annual Current Accrued Expense increased from Dec. 2023 ($0.04 Mil) to Dec. 2024 ($0.07 Mil) but then declined from Dec. 2024 ($0.07 Mil) to Dec. 2025 ($0.04 Mil).

NovelStem International Current Accrued Expense Related Terms

NovelStem International Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for NovelStem International's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovelStem International Current Accrued Expense Chart

NovelStem International Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 0.04 0.04 0.07 0.04

NovelStem International Quarterly Data
Mar13 Jun13 Sep13 Dec13 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.04 0.04 0.04

NovelStem International Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.04 Mil mean?
NovelStem International (NSTM) has a Current Accrued Expense of $0.04 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on NovelStem International and its competitors.
Is NovelStem International's Current Accrued Expense too high?
NovelStem International's current Current Accrued Expense is $0.04 Mil.
How does NovelStem International's Current Accrued Expense compare to NOTVQ and PRPH?
NovelStem International's Current Accrued Expense of $0.04 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Diagnostics & Research company?
A good Current Accrued Expense depends on the Medical Diagnostics & Research industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on NovelStem International and its competitors. NovelStem International's current Current Accrued Expense is $0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovelStem International stock overvalued right now?
NovelStem International (NSTM) has a current Current Accrued Expense of $0.04 Mil. The current Current Accrued Expense is $0.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For NovelStem International (NSTM), the current Current Accrued Expense is $0.04 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NovelStem International Business Description

Address 7740 Cavern Lane, Suite 100, Parkland, FL, USA, 33067
NovelStem International Corp is a holding company. Through its subsidiaries, the company is engaged in the development and commercialization of diagnostic technology that can predict patients' anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. The company also has an interest in a book publishing franchise.